Breaking News

Lonza’s API Mfg. Facility Expansion in China Begins Commercial Ops

Expanded capacity in Nansha will support mid-scale manufacturing to transition between early-phase and large-scale commercial production.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza’s new mid-scale manufacturing assets at its API manufacturing center in Nansha, China began commercial operations at the expanded manufacturing facility, which was part of a CHF 20 million investment announced in June 2021.   The expansion includes six 1,000L reactors, four 1,500L reactors, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The investments allow Lonza to provide customers with a smoother transition from small to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters